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Abstract
As master modulators of the human genome, miRNAs are involved in all cancer 
hallmarks, disrupting the normal function of their targets. By gaining or losing 
the function, miRNAs lead to the validation of tumor phenotype, its progression, 
and metastasis as well as to drug resistance. Increasing the evidence suggests that 
the modulation of miRNAs in cancer cells, by suppressing the oncogenic miRNAs 
(oncomiRs) and substituting the deficient tumor suppressive miRNAs (TS-miRNAs), 
could become a reliable tool for improving the cancer therapy. In this chapter, we will 
present an up-to-date overview of the role of miRNA-based therapeutics in oncology, 
highlighting their role in cancer management, how these therapies can be used, and 
which would be the future challenges related to miRNA-based therapies.
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1. Introduction
With an increasing incidence each year, cancer represents a major health prob-
lem worldwide, ranked second, after cardiovascular disease. According to the last 
estimation presented by the International Agency for Research on Cancer (IARC) 
in 2012, more than 14 million new cases of cancers were encountered, while the 
cancer-related deaths reached around 8.2 million people [1]. Unfortunately, the 
estimation for 2030 shows an increase in over 21 million new cancer cases and about 
13 million cancer deaths [2]. Cancer is characterized by changing the phenotype of 
the cells in which it occurs, leading to an uncontrolled proliferation, invasion, and 
metastasis. Albeit the cancers in early stages are treatable, especially by surgery, the 
major challenge is to treat cancers in advanced stages. Currently, the therapeutic 
regimens for treating the advanced cancers depend on several factors such as local-
ization, phenotype, and tumor size and are based on a combination of at least two 
of more approaches, represented by surgery, chemotherapy, radiotherapy, hormone 
therapy, and target therapy. Nevertheless, this anticancer armamentarium is not 
very efficient because about 90% of advanced cancers lead to metastasis and death 
ultimately [3]. Current anticancer therapies target either antiproliferative or pro-
apoptotic pathways of tumor cells or activate immune response against tumors, but 
Antisense Therapy
2
none of the currently available antitumor therapies target the molecular pathways 
involved in invasion and metastasis.
Tumor invasion and metastasis, as they were pointed out by Hanahan and 
Weinberg [4], represent one of the most important hallmarks of cancer, and 
therefore, exploiting these features of tumor cells could bring new data to develop 
more powerful anticancer therapies. Tumor invasion and metastasis are very 
complex processes that involve a series of sequential and interrelated steps. In this 
line, epithelial-to-mesenchymal transition (EMT) represents the most important 
event underlying the tumor invasion [5]. During EMT, tumor cells lose their 
epithelial characteristics and adhesion and acquire increased motility by shifting 
toward a mesenchymal phenotype while also diminishing apoptosis and senescence 
and gaining stem cell properties. The EMT regulation includes a network of many 
regulators, inducers, and effector molecules, which sustains tumor cell dissemina-
tion to distant organs [6].
The “omics” revolution has brought us new data about the complexity of signal-
ing pathways in cancer, the type of molecules that are involved in them, and which 
alterations are associated with cancer. Moreover, noncoding RNAs, including miR-
NAs, have proved their crucial role in the regulation of mRNA translation in both 
physiological and pathological status. Because of their high capacity to modulate 
mRNA expression, miRNAs are defined as master modulators of the human genome. 
Therefore, miRNAs are involved in all cancer hallmarks, disrupting the normal func-
tion of their targets. By gaining or losing the function, miRNAs lead to the validation 
of tumor phenotype, its progression, and metastasis as well as to drug resistance.
Increasing the evidence suggests that the modulation of miRNA expression 
in cancer cells, through the inhibition of oncogenic miRNAs (oncomiRs) and the 
substitution of deficient tumor suppressive miRNAs (TS-miRNAs), could represent 
a reliable tool for improving the cancer therapy. In this chapter, we will present 
an up-to-date overview about the role of miRNA-based therapeutics in oncology, 
highlighting their role in cancer management, how these therapies can be used, and 
which would be the future challenges related to miRNA-based therapies.
2. Short overview about biogenesis and function of miRNAs
If deciphering the whole human genome has represented a milestone of mod-
ern biology, the identification of its precise functionality is still a great challenge. 
However, by completing the ENCODE project, many data about how the human 
genome is functioning were revealed. Such as, it is estimated that about 1.5% of 
human genome includes coding DNA exons from protein-coding genes (PCGs), 
while the rest of 98% represents noncoding DNAs including regulatory sequences 
such as the ones defining noncoding RNAs (ncRNAs), as well as introns, and other 
DNA sequences with unknown functions [7].
About 80% of human genome is activated in cell physiology, and an impor-
tant part of noncoding regulatory elements involved in the regulation of PCGs 
includes noncoding RNAs. Since their recognition as a distinct class of biological 
regulators [8], micro-RNAs (miRNAs) have become the most studied species of 
noncoding RNAs. miRNAs are coded by genes located in almost all regions of the 
genome, including both PCGs and noncoding transcripts. About a half of miRNA 
genes are located in both intronic (40%) and exonic (10%) regions of noncod-
ing genes, while the majority of the other miRNA loci are located in intragenic 
regions of PCGs [9]. The first step of miRNA biogenesis includes the transcription 
of pri-miRNA, a primary long hairpin transcript with a length of hundreds or 
thousands of nucleotides (Figure 1). Furthermore, after its processing to a shorter 
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hairpin structure of about 70 nucleotides, the pre-miRNA is exported into the 
cytoplasm, where under enzymatic processing, it is reduced to a single-stranded 
RNA (mature miRNA) of about 21–23 nucleotides in length. Afterward, by its 
incorporation into Argonaute 2 protein and then in the RNA-induced silenc-
ing complex (RISC), the mature miRNA will function as a guide molecule for 
silencing complex, targeting specific mRNA transcripts, usually by base-pairing 
specific mRNA transcripts, in the 3′ untranslated region (3′ UTR). Targeting the 
mRNA by a specific miRNA leads to the translational repression of mRNA and its 
exonucleolytic decay [9].
Because of their capacity to modulate up to 60% of PCGs, miRNAs are defined 
as “master modulators” of the human genome [10]. An important feature of 
miRNAs is that a single miRNA can target up to 200 mRNAs, while a single mRNA 
can be modulated by different miRNAs [11]. Nevertheless, to increase the accuracy 
of miRNA-mRNA binding, several combinatorial prediction tools based on ther-
modynamic modeling and machine learning techniques have been developed lately 
[12, 13], bringing new understanding about how miRNAs can exert their regulatory 
function through a combinatorial-cooperative activity.
Figure 1. 
miRNA biogenesis. The miRNA biogenesis starts in the nucleus, with a pri-miRNA transcription. Afterward, 
the pri-miRNA is processed to a shorter hairpin structure of about 70 nucleotides, by Drosha and DGCR8, and 
it is exported in the cytoplasm by Exportin 5. After enzymatic processing by DICER, double-stranded miRNAs 
are reduced to a single-stranded mature RNA (21–23 nucleotides in length). Furthermore, by incorporating into 
Argonaute 2 and RISC, mature miRNA will target mRNA transcripts, usually in the 3′ UTR, leading to mRNA 
degradation or repression.
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At the moment, 48,885 mature miRNA products from 271 species, including 2654 
mature human miRNAs, have been reported in the latest available miRNA database 
(miRBase release 22; http://www.mirbase.org/) [14]. In normal phenotype, by their 
modulatory effects, miRNAs maintain the cell physiology, while by their aberrant 
expression, miRNAs lead to the validation of many diseases including cancer.
3. The role of miRNAs in cancer
Croce’s group established for the first time an association of mRNAs with cancer, 
indicating an alteration of miR-15a/16-1 cluster, in chronic lymphocytic leukemia 
[15]. Further functional analyses have demonstrated that miR-15 and miR-16 can 
target and suppress the expression of BCL2 oncogene, inducing the apoptosis. [16]. 
Through exploring the role of miRNAs, Croce’s group has demonstrated that miRNA 
profiling could be taken into consideration for characterizing the malignant pheno-
type [17], opening a new perspective for identifying new cancer-specific miRNAs. 
Interestingly, for poorly differentiated tumors, tissue miRNA profiling has revealed 
better diagnosis than mRNA profiling, highlighting their role as tumor biomarkers 
[18]. An important feature of miRNAs, given by their high stability in formalin-fixed 
paraffin embedded (FFPE) tissues, blood including serum and plasma, as well as 
other biological fluids such as urine, tears, breast milk, saliva, and seminal fluids, 
makes them important candidates for the discovery of new minimally invasive 
biomarkers [19, 20]
Therefore, a myriad of studies describing the role of miRNAs in cancer develop-
ment have been provided, with more than 21,565 papers that are published in PubMed 
today, when “miRNA, miR, microRNA, and cancer” are used as a string search.
Alteration of miRNA expression in cancer is due to genetic and epigenetic 
events. Genetic alterations include: chromosomal rearrangements or loss of het-
erozygosis (LOH) (e.g. miR-15a/16-1), gene amplification (e.g. miR-17-92 cluster, 
miR-155), deletions (e.g. let-7 family member), or mutations (e.g. miR-16) [15]. 
Moreover, genetic alteration may occur in the PCGs involved in the synthesis of the 
protein components of the Drosha, DGCR8, Exportin 5, Dicer, and AGO2, the main 
enzymes that process the biogenesis and activation of miRNAs. Pre- and post-
transcriptional controls of not only miRNA biogenesis but also epigenetic events, 
including methylation and acetylation, were also related to aberrant expression of 
tumor miRNAs [21, 22]. Not lastly, the presence of the single-nucleotide polymor-
phism (SNP) mutations in the miRNA-coding genes may lead to the alterations of 
mature miRNA structure, reducing its specificity to the mRNA target [23].
Functionality studies have demonstrated that the expression of oncogenes and 
tumor-suppressor genes in cancer is closely controlled by miRNAs (Figure 2). 
Such as, miRNAs that target and modulate the oncogenic expression are defined 
as tumor-suppressor miRNAs (TS-miRNAs), while the miRNAs that modulate the 
expression of tumor-suppressor genes are known as oncomiRs [24]. Genetic and 
epigenetic alterations occurring in cancer lead to “gain of function” of oncomiRs 
and inactivation or “loss of function” of TS-miR (Figure 2), which translate into 
regulating the expression of their targets through downregulation of tumor-
suppressor genes and upregulation of oncogenes, respectively [25]. miRNAs are 
involved in all hallmarks of cancer, including self-sufficiency in growth signals 
(let-7 family, miR-21), insensitivity to antigrowth signals (e.g. miR-17-92 cluster, 
miR-195), evasion from apoptosis (e.g. miR-34a, miR-185, miR-15/miR-16), 
limitless replicative potential (e.g. miR-372/373 cluster, miR221/222), angiogenesis 
(e.g. miR-210, miR-26, miR-15b, miR-155), invasion and metastases (e.g. miR-10b, 
miR-31, miR-200 family, miR-21, miR-15b), reprogramming energy metabolism 
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(e.g. miR-23a/b, miR-378, miR-143, miR-15b), evading immune destruction (e.g. 
miR-124, miR-155, miR-17-92), tumor-promoting inflammation (miR-23b, miR-
155, let-7d), and genomic instability (miR-21, miR-155, miR15b) [22, 26, 27].
4. Strategies used for miRNA-based therapies
4.1 miRNA inhibition therapies for oncomiRs
The choice to use mRNA-based therapies is based on the fact that the expression 
of mRNAs in tumor cells is altered, and tumor phenotype can be changed by the 
modulation of the miRNA expression [28].
Figure 2. 
The role of miRNAs in cancer and their use of miRNA-based therapy. (A) miRNAs that function as oncomiRs 
and TS-miRs. Tumors are characterized by aberrant upregulation of oncomiRs that lead to downregulation 
of tumor-suppressor genes and inactivation of TS-miRs reflected in overexpression of oncogenes. All of these 
contribute to tumor development, invasion, and metastasis as well as decrease cell death. (B) The use of 
anti-miRNA therapies leads to block the oncomiR activities, resulting in the upregulation of tumor-suppressor 
genes, while substituting TS-miR therapies increases the cellular level of TS-miRs, leading to the inactivation 
of oncogenes. The effects of miRNA-based therapy indicate an increase in cell death concomitantly with 
inactivation of tumor development.
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MiRNA inhibition therapy is used to suppress the expression of oncomiRs that are 
frequently overexpressed in human cancers and reestablish the normal expression 
of tumor-suppressor genes that are targeting directly (Figure 2). The therapy for 
miRNA inhibition includes the following agents: antisense anti-miR oligonucleotides 
(AMOs), locked nucleic acid (LNA) anti-miRs, antagomiRs, miRNA sponges, and 
small molecule inhibitors of miRNAs (SMIRs) [27]. The principle of this therapy 
consists of an isolation of the endogenous miRNAs in an unrecognizable configura-
tion, leading to inactivating and excluding the mature miRNAs from the RISC.
AMOs are single-stranded, chemically modified antisense oligonucleotides 
of about 17–22 nucleotides that are complementary to a miRNA of interest [28]. 
These antisense oligonucleotides anneal to the complementary mature miRNAs and 
inhibit their interaction with specific mRNA targets.
LNA anti-miRs represent an example of a modified antisense anti-miR oligo-
nucleotide [29]. LNA-modified oligonucleotides present a higher thermal stability 
and affinity for their miRNA target molecules, as well as a higher aqueous solubility 
and increased metabolic stability for in vivo delivery [30].
The antagomiRs are single-stranded RNA molecules of about 23 nucleotides in 
length complementary to miRNA targets that are chemically modified to increase the 
stability of the RNA and protect it from degradation [31]. One of the most important 
aspects of using these agents is due to their lack of inducing any immune response.
miRNA sponges represent a class of RNAs that include multiple artificial bind-
ing sites similar to those found in the endogenous miRNA targets. The expression 
vectors represent the source of miRNA sponge transcription, thus reducing the 
miRNA’s effects and increasing the expression of the miRNA’s native targets [32].
SMIRs are small molecules that suppress the miRNA biogenesis or block the 
interaction between a miRNA and the target. The inhibition therapy using SMIRs is 
an encouraging one due to the reduced time of production, approval, and cost [33].
4.1.1 Discussion
Krützfeldt et al. [31] demonstrated that intravenous administration of several 
antagomiRs toward miR-16, miR-122, miR-192, and miR-194 leads to a significant 
reduction in the corresponding endogenous miRNAs.
Moreover, an important positive effect observed in this study was that after the 
administration of antagomiR-122, the cholesterol levels in plasma have decreased. 
Due to the fact that, so far, the therapy using antagomiRs did not induce a signifi-
cant immune response, it is worth into consideration the development of a promis-
ing antisense therapy based on antagomiRs.
One of the main advantages of using locked nucleic acid (LNA) anti-miRs is that 
they present a higher thermal stability, high-affinity Watson-Crick hybridization 
with their RNA target molecules, higher aqueous solubility, and increased meta-
bolic stability for in vivo delivery. Overexpression of miR-21 is a common place in 
glioblastomas, and Griveau et al.’s [34] study was able to silence miR-21 in U87MG 
glioblastoma cell line, using a LNA conjugated to lipid nanocapsules (LNC). 
Another advantage of using LNA-LNC complexes in combination with external 
beam radiation is represented by the improvement of cell sensitivity to treatment.
4.2 miRNA replacement therapies for tumor-suppressor miRNAs
Also defined as miRNA restoration therapy, the replacement therapy with 
miRNAs includes the following agents: small molecules, synthetic miRNA mimics, 
and DNA plasmids encoding a miRNA gene that epigenetically alters endogenous 
expression of miRNAs [35].
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Small molecules in miRNA replacement therapy are represented by hypometh-
ylating agents (Decitabine or 5-azacytidine) and enoxacin, exerting a role in the 
nonspecific miRNA expression.
miRNA mimics are double-stranded synthetic RNAs, which are aimed to com-
pensate the lack of tumor-suppressor miRNAs by replacing the lost miRNAs. These 
chemically structures are loaded into RISC to provide the downstream inhibition of 
the target mRNAs [27].
4.2.1 Discussion
One of the main challenges of miRNA replacement therapy is represented by 
finding the most suitable, efficient, and specific delivery system. The efficacy of 
this therapy is significantly decreased by an unsuitable size of the vector or by gene 
expression. Since miRNAs can be introduced into cells using a similar technique to 
small interference RNAs [36], it is recommended to improve those techniques based 
on the insertion of synthetic miRNA mimics, DNA plasmids, and small molecules, 
as well as to improve the quality of molecules used for this type of therapy.
4.3 miRNA delivery systems
An important aspect that is worth considering in miRNA cancer therapy aims to 
use miRNA delivery systems. One of these delivery systems including microvesicles 
and exosomes aim to block miRNA-entrapped exosomes released by tumors. It is 
already demonstrated that miRNA-entrapped exosomes secreted by tumor cells can 
regulate gene expression in the receiving cells by binding to their target mRNAs 
[37]. The use of some agents that block specific miRNAs (such as LNA anti-miR-21 
and LNA anti-miR-29a) in tumor cells could lead to the reduction in miRNA-
entrapped exosomes, released by cancer cells [38]. However, an ideal delivery 
system meets the following criteria: protects the miRNAs from early degradation in 
the bloodstream, efficient distribution to the target cells, facilitates cellular uptake, 
does not induce an immune response, and made of biocompatible and biodegrad-
able materials [39].
The most commonly used vectors for miRNA delivery include viral and 
nonviral vectors. Previous data demonstrated that viral vectors mainly caused 
an immune response; therefore, the focus of the actual studies is on developing 
efficient nonviral vectors. Nonviral vectors are classified into three main groups, 
including polymeric vectors (polyethyleneimines, atelocollagen, polylactic-co-
glycolic acid, polyamidoamine dendrimers), lipid-based carriers (positively, 
negatively or neutral charged), and inorganic materials (gold, diamond, silica, and 
ferric oxide) [40].
The delivery system based on viral vectors transfers the pri-miRNA or mature 
miRNAs, usually a TS-miR, into a plasmid, which contains a viral promoter, an 
antibiotic resistance gene, and a restriction enzyme gene, to the tumor cells. After 
nuclear integration of the miRNA and further transcription, the mature miRNA 
represses the translation and/or induces the degradation of the target mRNA [41].
4.3.1 Discussion
One of the most studied classes of polymeric vectors was represented by polyeth-
ylenimines (PEIs) but was removed from clinical studies due to their high toxicity, 
given by an excessive positive charge, low biological degradation, and inactivation in 
serum caused by a nonspecific protein. Ibrahim et al. [42] have demonstrated that by 
using low molecular weight, PEIs as system delivery for miR-145 and miR-33a would 
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decrease the toxicity and increase the antitumor effect, in a model of colon carci-
noma. Recent studies [43, 44] have proved that codelivery of miR-200c with chitosan, 
a cationic polymer with a high specificity for nucleic acid binding, decreased the 
angiogenesis, invasion, EMT, and metastasis and increased the apoptosis, highlight-
ing the role of miRNA concentration in treatment effectiveness. Hao et al. [45] used 
miRNA (MiR-15a, miR16-1)/ATE-APT complex formed by atelocollagen (ATE), 
a type I collagen positively charged polymer, in combination with a RNA aptamer 
(APT) used as a ligand to target PCa cells that express prostate-specific membrane 
antigen (PSMA). Their study concluded that miRNA/ATE-APT complex was more 
efficient than an ATE-miRNA complex and that by using a PSMA-targeted system, 
the chances for selective killing of prostate cancer cells significantly would increase.
Moreover, it is worth into consideration the administration methods used for 
synthetic miRNAs (miRNA mimics) delivery into cells. Previous studies of Trang 
et al. have shown that both intratumoral and intravenous administration of let-7a 
mimics lead to the diminishing of non-small-cell lung cancer (NSCLC) tumor size 
in mouse models [46, 47].
As a future improvement in miRNA delivery systems, it is recommended to 
be synthetized proteins or peptides in order to be used as vector polymeric due to 
their low cytotoxicity and immunogenicity. Finding a suitable delivery system for a 
specific miR according to tumor cell type and the development of systems to target 
specific cancer membrane antigens still represent major challenges.
5. MicroRNAs in cancer therapies
5.1 miRNA candidates used in preclinical trials
Increasing the evidence has demonstrated that miRNA expression is modified in 
cancer, and restoring the level of cellular miRNA could underpin the development 
of miRNA-based therapies. Below we briefly describe miRNAs that are currently 
used in preclinical and clinical trials and also represent examples that affect the 
emerging hallmarks of cancer such as evasion from apoptosis (miR-15/16, miR-34 
cluster) [48], enabling replicative immortality (miR-34a) [48], activating invasion 
and metastasis (miR-10b) [49], tumor-promoting inflammation (miR-155), and 
genome instability and mutation (miR-155) [50].
5.1.1 miR-10b
Guessous et al. [51] observed that miR-10b is overexpressed in human glioblas-
toma and stem cell lines when compared to healthy tissues or astrocytes. After the 
modulation of miR-10b, they found out that the inhibition of miR-10b strongly 
reduced cell proliferation, invasion, and migration of glioblastoma and stem cell 
lines, whereas its overexpression caused cell migration and invasion. Moreover, 
in a previous study, Ma’s group [52] has demonstrated that the use of miR-10b 
antagomiRs was correlated with reduced metastasis both in cell-culture lines and in 
animal model of breast tumor-bearing mice. Thus, miR-10b inhibition both in vitro 
and in vivo significantly decreased miR-10b levels and increased levels of Hoxd10 
gene, an important miR-10b target. Curiously, the administration of miR-10b 
antagomiRs in vivo did not reduce primary mammary tumor growth but signifi-
cantly suppressed the development of lung metastases, highlighting its antimeta-
static role.
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5.1.2 miR-221
Since miR-221 overexpression alters multiple cancer pathways, it becomes a 
potential target for miRNA-based therapy. In order to validate the role of miR-221 in 
tumorigenesis, Callegari et al.[53] showed that in vivo delivery of an AMO anti-
miR-221 caused a significant decrease in the size and number of tumor nodules. 
Based on the results from their study, it was highlighted the promoter role of 
miR-221 in liver carcinogenesis, being also established a valuable animal model to 
investigate the anti-miRNA-based therapy for liver cancer.
Moreover, using a colorectal cancer model, Qin et al. [54] showed that miR-221 
promotes cell migration and invasion in vitro and metastasis in vivo, identifying 
tumor-suppressor RECK gene as a direct target of miR-221.
With regard to the role of miR-221 in tumorigenesis combined with the need 
to limit its expression, Brognara’s group demonstrated that a peptide nucleic acid 
conjugate targeted against miR-221 (Rpep-PNA-a221) caused a suppression of miR-
221 expression and an upregulation of its target p27Kip1 in two breast cancer cell lines 
(MCF-7 and MDA-MB-231), respectively [55]. On the other hand, in a recent study, 
Gallo et al. [56] evaluated the pharmacokinetic and pharmacodynamic properties 
of a locked nucleic acid anti-miR-221 (LNA-i-miR-221) in the models of mice and 
monkeys. Their data highlighted that LNA-anti-miR-221 has a short half-life, optimal 
tissue bioavailability and minimal urine excretion in both species. A very important 
aspect of their study was that no toxicity was present in the pilot monkey study. This 
finding defines the potential application of LNA-anti-miRNAs in clinical studies.
5.1.3 miR-222
Sometimes developing a miRNA-based therapy is difficult because the same 
miRNA can act both as an oncogene and as a tumor-suppressor gene, due to its 
multiple targets and mechanisms of action. Such an example in this way is repre-
sented by miR-222, which has a role of oncomiR in liver cancers, by targeting and 
suppressing the PTEN tumor-suppressor gene, or TS-miRNA, whose downregula-
tion in erythroblastic leukemia leads to the overexpression of c-KIT oncogene [27].
5.1.4 miR-34
miR-34 is one of the most important TS-miRs, being positively controlled by 
TP53 [57], repressed by MYC [58], and silenced by aberrant CpG methylation [59].
Overexpression of miR-34 was related to apoptosis and cell cycle arrest [60], while 
its underexpression was linked to different tumor types, including nonsmall-cell lung 
cancer (NSCLC) [61], breast cancer [62], or ovarian cancer [63]. Several studies have 
proved that ionizing radiation upregulates the levels of expression from different 
miR-34 family members in a variety of human cell types: miR-34b in lymphocytes 
[64], miR-34c in prostate cancer cell lines [65], and miR-34a in thyroid cells [66]. 
Consequently, to increase the therapeutic efficiency, some of the future studies 
should focus on the combined use of DNA damage response related to miRNAs and 
radio- or chemotherapy. By performing a miR-34 modulation, Trang et al. [47] have 
demonstrated that synthetic miR-34 mimics incorporated in a lipid-based particle was 
able to block tumor growth in a mouse model of nonsmall cell lung. Likewise, Daige 
et al. [67] have proved that the use of encapsulating miR-34a mimics into liposomes 
(MRX34) leads to increase the level of miR34a in liver tumors, followed by signifi-
cantly reducing several of its mRNA targets, and consequently tumor regression. 
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Based on these results, encapsulating miR-34a mimics into liposomes (MRX34, Mirna 
Therapeutics Inc.) was later proposed to be investigated in clinical trials [68].
5.1.5 miR-16
miR-16 represents another TS-miR whose decreased expression has been observed 
among different types of cancers, as well as in nonsmall cell lung cancer (NSCLC) 
[69], prostate cancer [70], or malignant pleural mesothelioma [71], making it a strong 
candidate for replacement therapy in future studies with potential use in clinical trials. 
The data presented by Takeshita et al. [72] revealed that systemic delivery of synthetic 
miR-16, conjugated to atelocollagen, significantly reduced bone metastases and tumor 
development in a prostate cancer animal model. Moreover, their in vitro data suggest 
that miR-16 suppresses prostate tumor growth by regulating the expression of genes 
associated with cell-cycle control and cellular proliferation such as CDK1 and CDK2. 
The Hao group has also revealed that miR-16-1/atelocollagen-aptamer complex used 
in a mice model of human prostate cancer with bone metastasis enhanced anticancer 
efficacy. They also demonstrated that the efficacy of this complex, including aptam-
ers, was higher, both in vitro and in vivo models than the other atelocollagen complexes 
that do not include aptamers. Re-expression of miR-16 mimic in malignant pleural 
mesothelioma cell lines and nude mouse models has caused the inhibition of tumor 
growth, correlated with downregulation of target genes Bcl-2 and CCND1 [71].
5.1.6 miR-155
miR-155, one of the first described oncomiRs [73], was identified as highly 
expressed in a wide range of tumors including chronic lymphocytic leukemia [74], 
lung cancer [75], breast cancer [76], acute myeloid leukemia [77], solid tumor 
including stomach, prostate, colon, pancreas [78], and melanoma [79].
OncomiR-155 was discovered to target RAD51, an important gene in the homol-
ogous recombination DNA repair pathway, and the clinical study of Gasparini 
et al. [80] for triple negative breast cancer revealed that low miR-155 expression 
level correlated with worse progression-free survival. Moreover, Pouliot et al. 
[81] reported a reduced expression of miR-155 in human epidermoid carcinoma 
cisplatin-resistant cell lines. Dysregulated expression of this miRNA sensitizes the 
cells to cisplatin-induced apoptosis by targeting WEE1 and CHK1 kinases. Based on 
these results, future studies are encouraged with the focus on the use of exogenous 
agents, such as mimics or anti-miRs to sensitize cancer cells to chemo- or radio-
therapy, thus overcoming resistance to therapy.
Alexander et al. [82] found that endogenous miR-155, an important microRNA 
that regulates inflammation, is released from dendritic cells within exosomes and 
transferred to recipient dendritic cells. Administration of miR-155 containing exo-
somes enhances inflammatory gene expression as a response to endotoxin-induced 
inflammation in mice. Their findings provide strong evidence that endogenous 
microRNAs follow a functional transfer between immune cells and represent a 
regulatory mechanism for inflammatory response.
More examples of tumor-suppressor miRNA mimics, which target multiple 
oncogenic transcripts, were recently presented by Hosseinahli et al. [41].
5.2 Clinical studies involving miRNA-based therapy
Given the results provided by in vitro and in vivo studies, several clinical trials 
including miRNA-based therapy in human cancers were subsequently initiated 
(Table 1).
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Company Drug Targeted 
miRNA
Therapy 
type
Cancer type Delivery 
system
Mechanism/effect Trial status Clinical trials. 
Gov identifier
Mirna 
Therapeutics. 
Inc
MRX34 miR-34 Mimic Nonsmall-cell lung 
carcinoma, small cell lung 
cancer, primary liver cancer 
lymphoma, melanoma, 
multiple myeloma, renal cell 
carcinoma
LNPs 
(Smarticles)
Reduction in the expression of 
oncogenes, tumor regression, 
enhanced the survival, and 
inhibited the growth of other 
nonhepatic tumors
Multicenter 
phase I 
terminated
NCT01829971
EnGeneIC MesomiR-1 miR-16 Mimic Malignant pleural 
mesothelioma, nonsmall cell 
lung cancer
EnGeneIC 
delivery 
vehicle
Strong inhibition of tumor 
growth
Multicenter 
phase I 
completed
NCT02369198
miRagen 
Therapeutics
MRG-106 miR-155 Anti-miR Cutaneous T cell lymphoma, 
mycosis fungoides, chronic 
lymphocytic leukemia, adult 
T-cell leukemia/lymphoma
LNA-modified 
antisense 
inhibitor
Reduce overexpression 
and of oncomiR, leading 
to decreasing aberrant cell 
proliferation
Multicenter 
phase I 
recruiting
NCT02580552
Table 1. 
Clinical trials using miRNA therapy in human cancers (adapted after Christopher et al. [87] and Rupaimoole et al. [88]).
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In April 2013, Mirna Therapeutics, Inc., a publicly traded company based 
in Carlsbad, California, which primarily focuses on anti-miRNAs technology, 
announced that their leading product candidate, MRX34, a mimic of miR-34 
encapsulated in a liposomal nanoparticle formulation, called NOV40, was the first 
microRNA mimic to enter clinical development. The multicenter phase I trial of 
MRX34 included patients diagnosed with primary liver cancer, nonsmall cell lung 
cancer (NSCLC), lymphoma, melanoma, multiple myeloma, or renal cell carci-
noma. The trial aimed to increase the number of intravenously doses with two times 
per week or five times per day schedule. In June 2016, a total of 99 patients suffering 
from HCC, NSCLC, or pancreatic cancer had been enrolled in the study [83]. The 
phase I clinical trial confirmed partial responses in a patient with metastasized 
hepatocellular carcinoma (HCC), a patient with advanced acral melanoma, and a 
patient with advanced renal cell carcinoma (RCC), evaluated through Response 
Evaluation Criteria in Solid Tumors (RECIST). Also, 14 patients were detected with 
stable disease (median duration 136 days; range 79–386 days). Results from white 
blood cell analysis indicated a significant reduction in two miR-34 target genes 
FOXP1 and BCL2. Nonetheless, because of the immune-related adverse responses 
involving patient deaths, the trial was finished. Since the cause of these immune 
reactions remains still unclear, preclinical trials will be need in order to better 
understand the immune-related toxicities. After passing successfully the phase I 
clinical trial, they intended to advance into two phase II clinical studies: one for 
patients diagnosed with advanced malignant melanoma and another for patients 
diagnosed with advanced renal cell carcinoma (RCC). In concordance with the 
advancements made by MRX34, their lead product candidate, through the clini-
cal development, miR-34 mimics represent a new promising class of replacement 
therapy used in cancer. Additionally, Cortez et al. [84] reported that p53 regulated 
PDL1 expression via miR-34 in nonsmall-cell lung cancer. Administration of miR-
34a mimics (MRX34), alone or in combination with radiotherapy (XRT), reduced 
PDL1 expression in the tumor and antagonized T-cell exhaustion.
In November 2014, EnGeneIC, a privately held Australian company in collabora-
tion with Asbestos Diseases Research Institute, Sydney, Australia, announced the start 
of phase I clinical trial using miR-16 mimic charged in nanocells, a bacterial-derived 
transfection system EDV™. The trial included patients suffering from malignant 
pleural mesothelioma (MPM) and advanced nonsmall cell lung cancer (NSCLC), 
refractory to standard therapy. miR-16 mimic-based therapy were delivered intrave-
nously, using EnGeneIC Delivery Vehicle (EDV)-Packaging, and were surface conju-
gated with an EGFR-targeting antibody in order to facilitate the target of tumor site 
[85]. Preliminary data presented by Van Zandwijk et al. [86] show manageable safety 
in response to infusion of 5 billion nanocells loaded with 1.5 μg miR-15/16 mimics as 
a first-dose level in the first five patients that had been enrolled. Because of the fact 
that this targomiR trial using miR-16 as a replacement therapy did not present adverse 
immune response and toxic effects, it is expected to continue to phase II study [86].
In March 2016, MiRagen Therapeutics, Inc., a privately held company based in 
Boulder, Colorado, announced the initiation of phase I clinical trial to investigate 
the anticancer product candidate: MRG-106, a synthetic microRNA antagonist 
of microRNA-155 (LNA anti-miR). The phase I clinical trial is currently tested in 
patients diagnosed with cutaneous T-cell lymphoma (CTCL) of the mycosis fungoi-
des (MF) subtype [89].
Despite some promising preclinical results, the outcome of MRX34 transla-
tional clinical trial using miR-16 as a replacement therapy, designed to restore the 
expression of miR-34 in patients diagnosed with different types of cancer, was 
discouraging due to adverse toxic effects. At present, this clinical trial is finished, 
and its suitability to further development to phase II study remains under question. 
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However, this drawback can be addressed by optimizing therapeutic doses and 
applying organ-specific administration routes [41].
6. Future challenges: new reliable miRNAs for target therapies
Epithelial-to-mesenchymal transition (EMT) allows tumor cells to enter the 
metastatic cascade by changing their morphological and molecular characteris-
tics, and it represents a wide spectrum that cancer cells keep transiting. The EMT 
program relies on an intricate network of signaling pathways that dictate a series 
of phenotypic changes in epithelial cells. One clearly visible aspect is the loss of 
apical-basal polarity and cell-to-cell interaction caused by the destabilization of 
tight junctions, decreased claudin, occludin, and E-cadherin repression by SNAIL, 
SLUG, ZEB, TWIST, and SMAD, and its interchange with N-cadherin, a process 
known as the “cadherin switch” [90, 91]. Moreover, the overexpression of vimentin, 
a cytoskeleton intermediate-filament protein of mesenchymal origin that connects 
the nucleus to the plasma membrane, enables filopodia formation and a fibroblastic 
spindle-like morphology. Vimentin was proved to be induced through Slug and Ras 
signaling, and it promotes cell movement and migration [92]. The next step is the 
degradation of extracellular matrix components under the activity of matrix metal-
loproteinases and the invasion of the surrounding stroma (Figure 3).
The EMT is coordinated by a series of signaling pathways triggered by either the 
tumor microenvironment or the intrinsic factors, and it falls under the incidence of 
regulatory noncoding RNAs, especially micro-RNAs [93].
This is the reason why finding potential microRNA targets for blocking EMT 
could support the efforts already made in blocking metastasis and improving cancer 
therapy strategies. Right below, we are succinctly reviewing the results of several 
studies that investigated the role of microRNAs in EMT and metastasis and their 
potential in becoming microRNA therapy targets (Table 2).
The influence of cancer-associated fibroblasts (CAFs) secreted exosomes over 
endometrial cancer progression was questioned in a study by Li et al. [94]. CAFs 
secreted exosomes contained significantly lower levels of miR-148b than normal 
fibroblasts, and miR-148b expression was lower in endometrial cancer specimens 
than in normal adjacent tissues. miR-148b was correlated with improved prognosis, 
in vitro and in vivo studies suggesting its role as an EMT inhibitor. Downregulation 
of DNMT1 oncogene was the mechanism proposed for miR-148b-mediated sup-
pression of endometrial cancer progression. Also, relating to the tumor micro-
environment, emerging evidence shows the prometastatic effect of a hypoxic 
Figure 3. 
The EMT-MET plasticity of tumor cells, their migration, and invasion as tumor circulating cells (CTCs).
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microenvironment over tumor cells. Acidic conditions were shown to promote 
miR-210 overexpression by activating HIF1 [95, 96]. In prostate cancer, high levels 
of miR-210 were detected in bone metastases, and they were correlated with poor 
prognosis of prostate cancer patients. Exogenously overexpression of miR-210-3p 
in cancer cell lines enhanced cell motility and migration as well as bone metastasis 
in mouse model by inducing NF-κB signaling and EMT. Moreover, miR-210-3p 
inhibition reversed EMT and impaired the metastatic potential of cancer cells [95]. 
Another study confirmed the hypoxia-induced EMT activation and metastasis by 
HIF1-miR-210 axis in breast cancer. Tang et al. [96] identified high expression of 
miR-210 in hypoxia grown breast cancer stem cells and in isolated human breast 
cancer stem cells. The overexpression of MiR-210 in poorly metastatic MCF7 cell 
lines leads to their invasiveness and migration in vitro as well as increasing meta-
static potential in vivo. One suggested mechanism is related to the direct binding 
of miR-210 to the Open Reading Frame (ORF) of the E-cadherin mRNA and its 
post-transcriptional inhibition in breast cancer cells.
miR-652 downregulation in the acidic microenvironment of pancreatic cancer 
promoted EMT by ZEB1 activation, and it was correlated with a progressive stage, 
lymphatic invasion, vascular infiltration, and distant metastasis. In vitro experiments 
showed that miR-652 overexpression has an antimetastatic effect by inducing MET in 
PANC-1-A miR-652-mimic transfected cells, and it reduced their migration and inva-
sion. Also, in vivo studies confirmed the in vitro results with lower tumor mass, fewer 
metastases, and overexpression of E-cadherin over vimentin/N-cadherin in mouse 
xenografts PANC-1-A miR-652-mimic transfected cells vs. miR-652 inhibitor [97].
Partially due to cancer tumors heterogeneity in construction and behavior and 
the relative novelty of noncoding RNAs as potential targets for cancer therapy, there 
are still missing bricks in understanding the mechanism that triggers the regulation 
of cancer-related microRNAs. However, as shown above, tumor microenvironment 
has a great impact over cancer progression, and probably understanding its role in 
modulating microRNA expression in tumor cells might bring light to new potential 
targets for improved therapy.
From a different perspective, there are many well-known pathways underlying 
cancer development and progression. Wnt signaling pathway represents one of the 
fundamental pathways involved in cell proliferation and specialization, as well as 
cell movement during both embryonic development and tissue homeostasis. The 
canonical Wnt signaling functions by regulating the amount of the transcriptional 
coactivator β-catenin, a molecule that controls key developmental gene expression 
programs [98]. Wnt signaling aberrations have been shown to regulate various 
processes that are important for cancer progression, including tumor initiation, 
tumor growth, cell senescence, cell death, differentiation, and metastasis. Wnt 
signaling molecules and downstream effectors can promote transcriptional changes 
in order to induce EMT in cancer cells while also being further activated by EMT in 
a continuous feedback loop [99].
Several microRNAs were proven to modulate Wnt signaling in EMT and cancer 
metastasis. In endometrial cancer, Wnt signaling can be activated by miR-652, 
which targets and inhibits retinoid orphan nuclear receptor alpha (RORA) gene. 
RORA represents a tumor-suppressor gene that represses the Wnt/β-catenin path-
way through attenuating β-catenin transcriptional activity. Expression of miR-652 
is frequently increased in human endometrial cancer tissues, its high expression 
being correlated with poor tumor differentiation, shorter overall survival, and 
recurrence. Overexpression of miR-652 in endometrial cancer cell promotes their 
proliferation and migration in vitro and in vivo [100].
Another metastasis enhancer, miR-374a, acts by activating the Wnt/β-catenin 
cascade and promoting EMT. miR-374a maintains constitutively activated 
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Wnt/β-catenin signaling by suppressing multiple negative regulators including 
WIF1, PTEN, and WNT5A. miR-374a was upregulated in primary tumor samples 
from breast cancer patients with distant metastases, and it was associated with 
poor metastasis-free survival. miR-374a transfection into poorly metastatic 
MCF7 cell line promoted its motility and invasiveness in vitro and lung metastasis 
forming abilities in BALB/c mice, while miR-374a knockdown in highly invasive 
MDA-MB-231 cells decreased their motility and metastatic potential [101].
On the other hand, microRNA-590-5p was found to function as a tumor-suppres-
sor in breast cancer, inhibiting EMT, cell migration, and invasion by downregulating 
the Wnt/β-catenin pathway. Quantitative RT-PCR analysis on breast tumor tissues 
and paired adjacent normal tissues showed that miR-590-5p was downregulated in 
breast cancer together with E-cadherin, while its target PITX2, b-catenin, Wnt-1, 
N-cadherin, and vimentin were upregulated. In vitro experiments and mouse xeno-
grafts showed that miR-590-5p upregulation or PITX2 silencing inhibits the activation 
of Wnt/β-catenin signaling pathway and suppresses the EMT of breast cancer [102].
Another metastasis inhibitor, miR-625, was characterized in different patholo-
gies, and surprisingly, it maintained its function, even though it was involved in 
different pathways. miR-625 was reported as downregulated in hepatocellular car-
cinoma, gastric cancer, and colorectal cancer, and its low expression was associated 
with local invasion, lymph node, and distant metastasis. Ectopic expression of miR-
625 induces suppression of migration and invasion of hepatocellular carcinoma cells 
by post-transcriptionally inhibiting IGF2BP1. Loss of IGF2BP1 suppressed F-actin 
polymerization, inhibiting the formation of cell protrusions, required for cell migra-
tion. The same effect was observed in vivo, where miR-625 overexpression decreased 
intrahepatic and lung metastasis [103]. Moreover, when it was ectopically induced, 
miR-625 suppressed the migration and invasion of gastric cancer cells as well as 
metastasis in nude mice by inhibiting ILK protein synthesis [98]. While the exact 
signaling pathway was not fully elucidated in colorectal cancer, ectopic miR-625 
expression inhibited cell migration and invasion and suppressed colorectal cancer 
cell metastasis in nude mice [99]. The aforementioned findings highlight miR-625 
as an interesting candidate for further in vivo studies in order to test its potential for 
developing a therapeutic microRNA for blocking invasion and metastasis.
A dual and somewhat contradictory behavior can be observed in the case of 
miR-409. While low miR-409 expression in breast cancer and nonsmall cell lung 
carcinoma (NSCLC) was associated with poorer prognosis and its ectopic uptake 
decreased the invasiveness of cancer cells [104, 105], it also seems to exert the nega-
tive effect in the case of prostate cancer, where it promotes tumorigenesis and EMT 
[106, 107]. Qi Song et al. [104] showed that miR-409 inhibits NSCLC cell migra-
tion, growth, and proliferation abilities by inhibiting SPIN1 translation. miR-409 
downregulates PI3K/AKT pathway in NSCLC and inhibits its downstream targets 
such as CREB1, BCL2, and Cyclin D. Overexpression of miR-409 led to fewer lung 
metastases in nude mice, confirming its antimetastatic potential. Interestingly, miR-
409 targeted the same pathway and suppressed cell growth and invasion in breast 
cancer. miR-409-3p inhibits the proliferation, migration, and invasion of breast 
cancer by targeting and suppressing the AKT expression. miR-409-3p was down-
regulated in several human tumors compared to their corresponding nontumor 
tissues [105]. On the other hand, miR-409-entrapped exosomes secreted by cancer-
associated fibroblasts (CAFs) and promoted EMT and prostate tumorigenesis. In 
their study, Josson et al. demonstrated that miR-409-3p was highly expressed in 
CAFs derived from human patients, and it was correlated with higher Gleason score 
in prostatic tissues. Moreover, the ectopic expression of miR-409 in normal prostate 
stromal fibroblasts conferred them a CAF phenotype in vitro. Exosome-mediated 
transport of miR-409 into normal prostate stromal cells induced cell growth and 
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miRNA Pathology Effect Target Mechanism Effect in vitro and in vivo Clinical associations Ref.
miR-
148b
Endometrial 
cancer
Metastasis 
inhibitor
Inhibits 
DNMT1
Anti-EMT, increased 
E-cadherin over 
vimentin, fibronectin, 
N-cadherin
Decreased motility and invasion in vitro, 
decreased metastasis in vivo
— [94]
miR-
210-3p
Prostate cancer Metastasis 
promoter
Inhibits 
TNIP1 and 
SOCS1
HIF1-miR-
210-3p- > enhances 
NF-κB signaling inducing 
EMT
Promoted EMT, invasion, and migration 
of Pca cells and bone metastasis of Pca 
cells in mouse
Overexpressed in bone metastatic 
tissues, correlates with high PSA 
levels, Gleason grade and bone 
metastasis status in prostate cancer 
patients
[95]
miR-210 Breast cancer Metastasis 
promoter
Inhibits 
E-cadherin 
synthesis
Blocks E-cadherin mRNA 
by binding to the ORF 
region
Upregulated in mammosphere 
cells, induced by hypoxia, promotes 
invasion, migration, proliferation, and 
self-renewal, induces EMT by loss of 
E-cadherin in vitro and leads to poorly 
differentiated tumors, high proliferation, 
more metastases and higher tumor mass 
in vivo
Upregulated in BCSC CD44+/
CD24-sorted from breast cancer 
tissue samples
[96]
miR-652 Pancreatic 
cancer
Metastasis 
inhibitor
Inhibits 
ZEB1
Acidic 
microenvironment-
miR-652 downregulation-
ZEB1 upregulation > EMT
Anti-EMT, reduced migration and 
invasion, promotes MET in vitro, lower 
tumor mass, fewer metastases, increased 
expression of E-cadherin vs. vimentin, 
N-cadherin in vivo
Downregulated in pancreatic 
cancer, correlated with progressive 
stage, lymphatic invasion, vascular 
infiltration, distant metastasis
[97]
miR-652 Endometrial 
cancer
Metastasis 
promoter
Inhibits 
RORA
Enhanced b-catenin 
expression, Wnt-b-
catenin signaling pathway
Increased proliferation, and increased 
metastasis potential in vitro and in vivo
Upregulated in EC, associated 
with poor differentiation, poor 
prognosis, shorter overall survival, 
and recurrence; not associated with 
cancer stage, localization, tumor 
size
[100]
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miRNA Pathology Effect Target Mechanism Effect in vitro and in vivo Clinical associations Ref.
miR-
374a
Breast cancer Metastasis 
promoter
Inhibits 
PTEN, 
WIF1, 
WNT5A
Wnt-b-catenin 
signaling, promoting the 
transcriptional activity of 
TCF/LEF
Induces EMT and enhanced motility in 
MCF7 transfected cells, decreases MDA 
cells motility in knockout, promotes 
lung metastases with MCF7 miR-374a 
transfected cells, impaired MDA-435 
metastases by the administration of 
antagomiR
Upregulated in patients that 
presented metastases within the 
51 months follow up; associated 
with low WIF1, PTEN, and WNT5A 
expression in tumor samples; high 
b-catenin low E-cadherin in miR-
374a overexpressing samples
[101]
miR-
590-5p
Breast cancer Metastasis 
inhibitor
Inhibits 
PITX2
Blocks Wnt signaling 
induced by PITX2
Upregulation of miR-590 inhibits 
EMT genes, inhibits proliferation after 
48-72 h, impairs migration and invasion 
of cancer cells, and promotes smaller 
tumor size for miR-590 mimic or PITX2 
inhibition and less lung and lymphatic 
metastases in nude mice
Downregulated in breast cancer 
tissues vs. normal tissue, together 
with E-cadherin, while PITX2, 
b-catenin, Wnt-1, N-cadherin, and 
vimentin are upregulated
[102]
miR-625 Hepatocellular 
carcinoma
Metastasis 
inhibitor
Inhibits 
IGF2BP1
PTEN and Akt signaling 
downregulation, 
inhibiting F-actin 
polymerization
Suppressed migration and invasion, 
proliferation was not influenced in cell 
lines, decreased intrahepatic and lung 
metastasis in mice xenografts
Downregulated in HCC, correlated 
with aggressiveness of cancer and 
tumor metastasis
[103]
miR-625 Gastric cancer Metastasis 
inhibitor
Inhibits ILK Suppressed LIMS1-ILK-
parvin axis signaling
Reduced migration and invasion 
rate in vitro, suppressed motility and 
extravasation from vessels, fewer lung 
metastatic nodes
Downregulated in gastric cancer, 
associated with lymph-node 
metastasis; no relation with tumor 
localization, differentiation, and 
local invasion
[98]
miR-625 Colorectal 
cancer
Metastasis 
inhibitor
— — Reduced migration in cancer cell lines; 
fewer and smaller liver metastases in 
mouse xenografts
Downregulated in cancer tissues, 
associated with lymph node and 
liver metastases and lower overall 
survival rate in 5 years
[99]
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miR-409 NSCLC Metastasis 
inhibitor
Inhibits 
SPIN1
Downregulation of 
SPIN1-AKT signaling
Inhibits cell growth, proliferation, and 
migration in vitro; fewer lung metastatic 
foci in vivo
Downregulated in NSLC tissues, 
correlated with tumor size, stage, 
pleural invasion, and metastasis; 
worse overall survival and disease-
free survival
[104]
miR-
409-3p
Breast cancer Metastasis 
inhibitor
Inhibits 
AKT1 p
Downregulation of PI3K-
AKT pathway
Inhibited breast cancer cell proliferation, 
migration, and invasion suppressed 
tumor growth in vivo
Downregulated to a significant 
extent in tumor samples, relative to 
the corresponding nontumor tissues
[105]
miR-
409-
3p/5p
Prostate cancer Metastasis 
promoter
Inhibits 
RSU1 and 
STAG2
Upregulation of Ras and 
Akt signaling
Induces EMT in normal prostate 
epithelia, promotes tumorigenicity and 
stemness in vivo
Upregulated in human prostatic 
tissues with higher Gleason score 
and prostate cancer bone metastasis
[106]
miR-
409-
3p/5p
Prostate cancer Metastasis 
promoter
Inhibits 
STAG2 and 
RSU1
Upregulation of Ras-ILK 
signaling
Induction of an EMT phenotype, 
decreased E-cadherin, increased 
vimentin, b-actin and downregulation of 
tumor suppressing genes
Higher miR-409 expression in the 
stromal fibroblasts, correlated with 
higher Gleason score in prostatic 
tissues
[107]
miR-
409-5p
Breast cancer Metastasis 
promoter
Inhibits 
RSU1
Upregulation of Ras 
signaling
Induces proliferation and migration in 
cancer cells and tumor growth in mice 
xenografts
Upregulation in breast can 
carcinoma tissues, correlated with 
shorter survival
[108]
Table 2. 
In vitro and in vivo validated miRNAs related to EMT, invasion, and metastasis that could represent future therapy targets.
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EMT in vitro and in vivo. In this case, the predicted targets of miR-409 were the 
tumor-suppressor proteins STAG2 and RSU1, which appeared downregulated 
[108]. Considering these, it would be worth exploring if miR-409 has a positive or a 
negative impact over EMT and metastasis in more human cancers, and if it could be 
taken into consideration as a future miRNA therapy target.
Table 2 comprises a set of microRNAs that were evaluated both in vitro and in 
vivo, while also being analyzed in tumor samples, in correlation with the clinical 
outcome of the patients. As it can be easily observed, the effect of microRNAs in 
modulating EMT and metastasis-related pathways varies in different cancer types. 
In certain situations, the same microRNA can induce completely opposite outcomes 
by targeting multiple signaling pathways. This would be one of the biggest chal-
lenges that need to be overcome when designing new microRNA-based therapeutic 
compounds, and it is, at the same time, an interesting research niche worth explor-
ing, especially for miR-625, that maintained its anti-EMT function in three different 
cancer types (hepatocellular carcinoma, gastric cancer, and colorectal cancer) and 
miR-409 that is able to target multiple pathways with opposing effects in NSCLC, 
breast cancer, and prostate cancer.
7. Conclusions
miRNAs represent key modulators of the human genome because of their 
capacity to affect up to 60% of protein-coding genes. In cancer, genetic and epi-
genetic events lead to the alteration of miRNA expression and consequently their 
mRNA target genes. Functional studies have demonstrated that miRNA modula-
tion in tumor cells causes changes in the phenotype, leading to increased apoptosis 
and cell death, suppression of tumor development, invasion, and metastasis by 
inhibiting the oncogenic miRNAs (oncomiRs) and/or substituting the deficient 
tumor suppressive miRNAs (TS-miRNAs). Considering the encouraging preclini-
cal and clinical data, miRNA-based therapy could become a reliable tool in cancer 
management.
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